Perspectives on nano-nutraceuticals to manage pre and post COVID-19 infections

Dubey, Ankit Kumar; Chaudhry, Suman Kumar; Singh, Harikesh Bahadur; Gupta, Vijai Kumar

doi:10.1016/j.btre.2022.e00712

Cited by 28 publications

(27 citation statements)

References 160 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanosystems can be used as a therapeutic option for the successful delivery of drugs for Omicron 140 . Nano‐neutraceuticals, in the shape of nanosystem‐based masks, gloves and disinfectants, are another example of using nanotechnology for overcoming the higher transmissibility of Omicron 141 . Nanotechnology can also be used to improve therapeutic methods and develop vaccines with a higher efficacy (lipid nanoparticles).…”

Section: Introductionmentioning

confidence: 99%

“… 140 Nano‐neutraceuticals, in the shape of nanosystem‐based masks, gloves and disinfectants, are another example of using nanotechnology for overcoming the higher transmissibility of Omicron. 141 Nanotechnology can also be used to improve therapeutic methods and develop vaccines with a higher efficacy (lipid nanoparticles). Nanosystems can be used for the delivery of vaccines to the target site of the virus using smart nanocarriers.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

OMICRON: Virology, immunopathogenesis, and laboratory diagnosis

Bazargan

Elahi

Esmaeilzadeh

2022

The Journal of Gene Medicine

View full text Add to dashboard Cite

Since its emersion, coronavirus disease 2019 (COVID‐19) has been a significant global dilemma. Several mutations in the severe acute respiratory virus (SARS‐Co‐2) genome has given rise to different variants with various levels of transmissibility, severity and mortality. Up until November 2021, the variants of concern declared by the World Health Organization were Alpha, Beta, Delta and Gamma. Since then, a novel variant named Omicron (B.1.1.529) has been developed. BA.1, BA.1.1, BA.2 and BA.3 are four known subvariants of Omicron. The Omicron variant involves new mutations in its spike protein, most of which are in its receptor binding site, and increase its transmissibility and decrease its antibody and vaccine response. Understanding the virology and mutations of Omicron is necessary for developing diagnostic and therapeutic methods. Moreover, important issues, such as the risk of re‐infection, the response to different kinds of vaccines, the need for a booster vaccine dose and the increased risk of Omicron infection in pediatrics, need to be addressed. In this article, we provide an overview of the biological and immunopathological properties of Omicron and its subvariants, its clinical signs and symptoms, Omicron and pediatrics, vaccines against Omicron, re‐infection with Omicron, diagnostic approaches and specific challenges of Omicron in the successful control and management of the rapid global spread of this variant.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

OMICRON: Virology, immunopathogenesis, and laboratory diagnosis

Bazargan

Elahi

Esmaeilzadeh

2022

The Journal of Gene Medicine

View full text Add to dashboard Cite

show abstract

“…However, newer systems also should go through stringent approval criteria, as complete recovery from illness and long-term effectiveness of these agents still need multidisciplinary validation in terms of biocompatibility. 255 …”

Section: Prospects Of Nano-biomed Technology For Mutating Sars-cov-2mentioning

confidence: 99%

Advances in Nanomaterial-Based Platforms to Combat COVID-19: Diagnostics, Preventions, Therapeutics, and Vaccine Developments

Mahmud¹,

Anik

Hossain

et al. 2022

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

The COVID-19 pandemic caused by the SARS-CoV-2, a ribonucleic acid (RNA) virus that emerged less than two years ago but has caused nearly 6.1 million deaths to date. Recently developed variants of the SARS-CoV-2 virus have been shown to be more potent and expanded at a faster rate. Until now, there is no specific and effective treatment for SARS-CoV-2 in terms of reliable and sustainable recovery. Precaution, prevention, and vaccinations are the only ways to keep the pandemic situation under control. Medical and scientific professionals are now focusing on the repurposing of previous technology and trying to develop more fruitful methodologies to detect the presence of viruses, treat the patients, precautionary items, and vaccine developments. Nanomedicine or nanobased platforms can play a crucial role in these fronts. Researchers are working on many effective approaches by nanosized particles to combat SARS-CoV-2. The role of a nanobased platform to combat SARS-CoV-2 is extremely diverse (i.e., mark to personal protective suit, rapid diagnostic tool to targeted treatment, and vaccine developments). Although there are many theoretical possibilities of a nanobased platform to combat SARS-CoV-2, until now there is an inadequate number of research targeting SARS-CoV-2 to explore such scenarios. This unique mini-review aims to compile and elaborate on the recent advances of nanobased approaches from prevention, diagnostics, treatment to vaccine developments against SARS-CoV-2, and associated challenges.

show abstract

“…Dubey et al. [11] have explained in their review article how to design nano-nutraceuticals to deactivate virus that can inhibit the binding of the virus with receptors and support immunity and accomplish pre and post COVID-19 infection. The major antibiotics such as Abyssomicin C, allicin, anthracimycin, berberine, biochanin A, caffeic acid, daptomycin, kibdelomycin, piperine, platensimycin, plazomicin, taxifolin, teixobactin, and thymol which showed strong antibacterial activity against ESKAPE ( Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.)…”

Section: Editorialmentioning

confidence: 99%